PATENT CLAIM ANALYSIS

Application Number: 16076479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), novel uses of multi-specific binding agents for bridging cells, and methods of therapy. The invention also provides variation-matched engineered cells.

Claim (Index 97):
The method of  claim 96 , wherein the ligand is a human protein ligand, the subject is a human and\n (a) the ligand is encoded in the immune cell by a non-endogenous nucleotide sequence (S1) comprising a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the ligand; and (b) wherein the immune cell is comprised by an autologous or allogeneic transplant that has been administered to the subject, wherein the genome of the subject comprises said SNP1 before administration of the transplant thereto.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.34483
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15866222', '15934770', '15105074', '15637734', '15106783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7387264442956348
- 35 USC 102 Novelty (BERT): 0.5236931623329305
- Combined Prediction Score: 0.7172231160993645
- Mean Citation Score: 319.32395
- Max Citation Score: 322.89294
- Similarity Product: 191.96181760737767

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test